Mohamed H. Khalil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed H. Khalil has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Abdelazem Khaled
Zagazig University Faculty of Human Medicine, Zagazig, Egypt
1 shared publication - Ahmed Abdelsalam
Faculty of Medicine, Delta University for Science and Technology, Egypt
1 shared publication - Ahmed Elshahat
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publication - Ahmed Mostafa Amin
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publication - Ahmed Raja Albishti
Faculty of Medicine, University of Tripoli, Tripoli, Libya
1 shared publication - Ali Nagy Shelbaya
Faculty of Medicine, New Mansoura University, New Mansoura, Egypt
1 shared publication
Latest Publications
- Open Access
- 25 April 2026
- Published by American Society for Inclusion, Diversity, and Equity in Healthcare in ASIDE Internal Medicine
- Vol. 2 (3) , 55-64
Adjunctive Remotely Supervised tDCS in Multiple Sclerosis: A GRADE-Assessed Meta-analysis of Sham-Controlled Trials on Cognitive, Fatigue, Mobility, and Quality-of-Life Outcomes
Background: Multiple sclerosis (MS) is an immune-mediated disorder characterized by demyelination within the central nervous system, resulting in fatigue, pain, cognitive dysfunction, and motor impairment. Remotely supervised transcranial direct current stimulation (RS‑tDCS) is a noninvasive, low-cost, home-based intervention that modulates neuronal excitability and enhances neural network function, potentially benefiting individuals with MS. This meta-analysis aimed to evaluate the efficacy of RS‑tDCS in MS. Methods: A systematic search was conducted in PubMed, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) evaluating RS‑tDCS in MS. The primary outcome was information‑processing speed. Statistical analyses were performed using R software (version 4.5.0) and a random‑effects model to calculate pooled standardized mean differences (SMDs) and mean differences (MDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane ROB‑2 tool. Results: Five RCTs, most featuring co-interventions alongside RS-tDCS in both study arms and one specifically targeting MS patients with cannabis use disorder, including 291 participants, were analyzed. Active RS‑tDCS did not significantly improve information‑processing speed (SMD = 0.20; 95% CI: –0.06 to 0.45; P = 0.13, n studies: 4). No significant effects were observed for secondary outcomes. Conclusion: Evidence from five heterogeneous RCTs, predominantly featuring co-interventions, shows no clear benefit of RS-tDCS for MS cognitive or functional outcomes (very low to low certainty). This highlights substantial uncertainty; larger standalone trials are required.
- 25 April 2026
- Published by American Society for Inclusion, Diversity, and Equity in Healthcare in ASIDE Internal Medicine
- Vol. 2 (3) , 55-64
Open AccessAdjunctive Remotely Supervised tDCS in Multiple Sclerosis: A GRADE-Assessed Meta-analysis of Sham-Controlled Trials on Cognitive, Fatigue, Mobility, and Quality-of-Life Outcomes
Background: Multiple sclerosis (MS) is an immune-mediated disorder characterized by demyelination within the central nervous system, resulting in fatigue, pain, cognitive dysfunction, and motor impairment. Remotely supervised transcranial direct current stimulation (RS‑tDCS) is a noninvasive, low-cost, home-based intervention that modulates neuronal excitability and enhances neural network function, potentially benefiting individuals with MS. This meta-analysis aimed to evaluate the efficacy of RS‑tDCS in MS. Methods: A systematic search was conducted in PubMed, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) evaluating RS‑tDCS in MS. The primary outcome was information‑processing speed. Statistical analyses were performed using R software (version 4.5.0) and a random‑effects model to calculate pooled standardized mean differences (SMDs) and mean differences (MDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane ROB‑2 tool. Results: Five RCTs, most featuring co-interventions alongside RS-tDCS in both study arms and one specifically targeting MS patients with cannabis use disorder, including 291 participants, were analyzed. Active RS‑tDCS did not significantly improve information‑processing speed (SMD = 0.20; 95% CI: –0.06 to 0.45; P = 0.13, n studies: 4). No significant effects were observed for secondary outcomes. Conclusion: Evidence from five heterogeneous RCTs, predominantly featuring co-interventions, shows no clear benefit of RS-tDCS for MS cognitive or functional outcomes (very low to low certainty). This highlights substantial uncertainty; larger standalone trials are required.
- 19 January 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (4) , F352-F359
Effect of different feeding approaches on growth, neonatal morbidities, mortality and neurodevelopmental outcome in preterm infants: a systematic review and network meta-analysis
Objective: To compare feeding strategies on preterm infants’ growth during hospitalisation, neonatal morbidities, mortality and neurodevelopmental outcome (NDO) at 18–26 months corrected age. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension statement for network meta-analysis . We searched five medical databases for randomised controlled trials comparing different feeding approaches in preterm infants and their effects on growth, neonatal morbidities, mortality and NDO. The Cochrane Collaboration’s tool was used to assess the risk of bias. We used a random-effects model. Pooled mean differences (MD) or risk ratios with 95% CIs were calculated. Results: Ninety-five studies (9663 infants) were included. Human milk (HM) with bovine milk fortifier (BMF) (adjusted according to blood urea nitrogen) achieved the best length increment (MD=0.56 cm/week; 95% CI 0.19 to 0.93). Notably, HM+BMF (3.5 gm/kg/d protein) showed the best head circumference growth (MD 0.46 cm/week; 95% CI 0.10 to 0.81) but no significant difference in weight gain. There were no significant differences in neonatal morbidities/mortality. While MOM|+PTF (supp) displayed significantly lower NDO delay in the domain of mild cognitive delay. Conclusion: Overall, there is a lack of strong evidence to support a specific enteral feeding strategy and further high-quality research is required. Targeted HM fortification appears to improve head growth, while adjusted fortification enhances length. Given the significant inconsistency detected, which may compromise the reliability of the network estimates, these results must be interpreted carefully.
- 19 January 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (4) , F352-F359
Effect of different feeding approaches on growth, neonatal morbidities, mortality and neurodevelopmental outcome in preterm infants: a systematic review and network meta-analysis
Objective: To compare feeding strategies on preterm infants’ growth during hospitalisation, neonatal morbidities, mortality and neurodevelopmental outcome (NDO) at 18–26 months corrected age. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension statement for network meta-analysis . We searched five medical databases for randomised controlled trials comparing different feeding approaches in preterm infants and their effects on growth, neonatal morbidities, mortality and NDO. The Cochrane Collaboration’s tool was used to assess the risk of bias. We used a random-effects model. Pooled mean differences (MD) or risk ratios with 95% CIs were calculated. Results: Ninety-five studies (9663 infants) were included. Human milk (HM) with bovine milk fortifier (BMF) (adjusted according to blood urea nitrogen) achieved the best length increment (MD=0.56 cm/week; 95% CI 0.19 to 0.93). Notably, HM+BMF (3.5 gm/kg/d protein) showed the best head circumference growth (MD 0.46 cm/week; 95% CI 0.10 to 0.81) but no significant difference in weight gain. There were no significant differences in neonatal morbidities/mortality. While MOM|+PTF (supp) displayed significantly lower NDO delay in the domain of mild cognitive delay. Conclusion: Overall, there is a lack of strong evidence to support a specific enteral feeding strategy and further high-quality research is required. Targeted HM fortification appears to improve head growth, while adjusted fortification enhances length. Given the significant inconsistency detected, which may compromise the reliability of the network estimates, these results must be interpreted carefully.
- 9 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 106980
Exposure to tobacco smoke during pregnancy and the risk of multiple sclerosis in offspring: A systematic review and meta-analysis
- 9 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 106980
Exposure to tobacco smoke during pregnancy and the risk of multiple sclerosis in offspring: A systematic review and meta-analysis